Jeffrey R Curtis
Foundation for Advancing Science Technology Education and Research · University of Alabama at Birmingham
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jeffrey R Curtis as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:19 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT05080218 · COVID-19 VaccinE Response in Rheumatology PatientsJeffrey Curtis · completed · Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis · principal investigator
- Ph2NCT02538341 · Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)University of Alabama at Birmingham · completed · Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis · principal investigator
- N/ANCT01112098 · Improving Quality of Osteoporosis Care Through Patient StorytellingUniversity of Alabama at Birmingham · completed · Osteoporosis · principal investigator
- N/ANCT01109472 · Improving Osteoporosis Care in a Home Health SettingUniversity of Alabama at Birmingham · completed · Osteoporosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 7 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Administrative CoreP30AR072583 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2020 to 2026 · $257,886 awarded in 2026Same name and institution; not confirmed by an ID
- Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)UM1AR065705 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2014 to 2019 · $654,455 awarded in 2019Same name and institution; not confirmed by an ID
- Facilitating Treat-to-Target Using Novel Health Technology with Decision supportP60AR064172 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2013 to 2017 · $301,164 awarded in 2017Same name and institution; not confirmed by an ID
- A Novel Centralized Virtual Gout Clinic for Chronic Gout ManagementP50AR060772 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2012 to 2016 · $341,660 awarded in 2016Same name and institution; not confirmed by an ID
- Longitudinal Comparative Effectiveness & Safety of Biologics in AutoimmunityR01HS018517 · AHRQ · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2009 to 2013 · $449,835 awarded in 2013Same name and institution; not confirmed by an ID
- Ethnic Differences in the Risk of Fracture and Vascular DiseaseK23AR053351 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2007 to 2011 · $129,708 awarded in 2011Same name and institution; not confirmed by an ID
- The TAKEOFF Trial: Clinical Trial Planning GrantR34AR060280 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2011 · $146,500 awarded in 2011Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:19 UTC. The ranking covers the 200 most relevant of 145 PubMed records, and a shared surname and initials can bring in a namesake. All 145 on PubMed
- A communication strategy and brochure for relatives of patients dying in the ICU.N Engl J Med · 2007904 citationsRCR 28.4
- Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.Lancet Oncol · 2016361 citationsRCR 10.4
- 326 citationsRCR 14.7
- Ultraconservative and cariostatic sealed restorations: results at year 10.J Am Dent Assoc · 1998312 citationsRCR 19.7
- Randomized Trial of Communication Facilitators to Reduce Family Distress and Intensity of End-of-Life Care.Am J Respir Crit Care Med · 2016302 citationsRCR 15.6
- 298 citationsRCR 10.7
- A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.Gastroenterology · 2021274 citationsRCR 18.8
- Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.Arthritis Res Ther · 2019260 citationsRCR 12.1
- Effect of a quality-improvement intervention on end-of-life care in the intensive care unit: a randomized trial.Am J Respir Crit Care Med · 2011236 citationsRCR 8.5
- 228 citationsRCR 8.1